Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Catapulting clopidogrel pharmacogenomics forward

The antiplatelet drug clopidogrel helps prevent stent-associated thrombosis, but the antiplatelet effects are quite variable and the clinical consequences can be serious. New findings show that the variability in clopidogrel efficacy is affected by the enzyme paraoxonase-1 (PON1), which is required for clopidogrel bioactivation (pages 110–116).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Figure 1: There are two major steps in the metabolism of clopidogrel.

Marina Corral


  1. Topol, E.J. Textbook of Interventional Cardiology. 5th edn. Ch. 66, 1221–1240 (Elsevier, Philadelphia, 2008).

    Google Scholar 

  2. Winslow, R. Plavix rival gains from studies. Wall Street Journal (30 August 2010).

    Google Scholar 

  3. Serebruany, V.L. et al. J. Am. Coll. Cardiol. 45, 246–251 (2005).

    Article  CAS  Google Scholar 

  4. Mauri, L. et al. N. Engl. J. Med. 356, 1020–1029 (2007).

    Article  CAS  Google Scholar 

  5. Bouman, H.J. et al. Nat. Med. 17, 110–116 (2011).

    Article  CAS  Google Scholar 

  6. Hulot, J.S. et al. Blood 108, 2244–2247 (2006).

    Article  CAS  Google Scholar 

  7. Simon, T. et al. N. Engl. J. Med. 360, 363–375 (2009).

    Article  CAS  Google Scholar 

  8. Collet, J.P. et al. Lancet 373, 309–317 (2009).

    Article  CAS  Google Scholar 

  9. Mega, J.L. et al. N. Engl. J. Med. 360, 354–362 (2009).

    Article  CAS  Google Scholar 

  10. Hulot, J.S. et al. J. Am. Coll. Cardiol. 56, 134–143 (2010).

    Article  CAS  Google Scholar 

  11. Mega, J.L. et al. J. Am. Med. Assoc. 304, 1821–1830 (2010).

    Article  CAS  Google Scholar 

  12. Shuldiner, A.R. et al. J. Am. Med. Assoc. 302, 849–857 (2009).

    Article  CAS  Google Scholar 

  13. Damani, S.B. & Topol, E.J. J. Am. Coll. Cardiol. 56, 109–111 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Eric J Topol.

Ethics declarations

Competing interests

E.J.T. is a consultant/advisor to Sanofi-Aventis, Daiichi and Quest Diagnostics.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Topol, E., Schork, N. Catapulting clopidogrel pharmacogenomics forward. Nat Med 17, 40–41 (2011).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing